|
ES2527760T3
(es)
|
1998-07-23 |
2015-01-29 |
Yeda Research And Development Co., Ltd. |
Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
|
|
IL141021A0
(en)
|
1998-07-23 |
2002-02-10 |
Yeda Res & Dev |
Treatment of autoimmune conditions with copolymer 1 and related copolymers
|
|
WO2000005249A2
(en)
*
|
1998-07-23 |
2000-02-03 |
The President And Fellows Of Harvard College |
Synthetic peptides and methods of use for autoimmune disease therapies
|
|
US6800287B2
(en)
|
1998-09-25 |
2004-10-05 |
Yeda Research And Development Co., Ltd. |
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
|
|
US6872739B1
(en)
*
|
1999-06-04 |
2005-03-29 |
Vereniging Voor Christelijk Wetenshappelikjk Onderwijs |
Use of riluzole for the treatment of multiple sclerosis
|
|
JP2003522121A
(ja)
*
|
1999-06-04 |
2003-07-22 |
フェレニヒング フォール クリステレイク ウェテンスハッペリキク オンデルウェイス |
多発性硬化症の処置のためのリルゾールの使用
|
|
IL150895A0
(en)
*
|
2000-02-18 |
2003-02-12 |
Teva Pharma |
Oral, nasal and pulmonary formulations of copolymer-1
|
|
US7022663B2
(en)
|
2000-02-18 |
2006-04-04 |
Yeda Research And Development Co., Ltd. |
Oral, nasal and pulmonary dosage formulations of copolymer 1
|
|
US20020077278A1
(en)
|
2000-06-05 |
2002-06-20 |
Yong V. Wee |
Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
|
|
HUP0302333A3
(en)
*
|
2000-06-05 |
2005-07-28 |
Teva Pharma |
The use of glatiramer acetate (copolymer 1) for the preparation of pharmaceutical compositions available in the treatment of central nervous system disorders
|
|
WO2002076503A1
(en)
|
2000-06-20 |
2002-10-03 |
Mayo Foundation For Medical Education And Research |
Treatment of central nervous system diseases by antibodies against glatiramer acetate
|
|
US7429374B2
(en)
|
2001-12-04 |
2008-09-30 |
Teva Pharmaceutical Industries, Ltd. |
Process for the measurement of the potency of glatiramer acetate
|
|
DK1485127T3
(da)
|
2002-02-25 |
2011-10-03 |
Elan Pharm Inc |
Anvendelse af midler til behandling af inflammation
|
|
CA2514117A1
(en)
*
|
2003-01-24 |
2004-08-12 |
Elan Pharmaceuticals, Inc. |
Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
|
|
HRP20160455T1
(hr)
|
2004-09-09 |
2016-07-15 |
Yeda Research And Development Co., Ltd. |
Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene
|
|
NZ598661A
(en)
|
2009-08-20 |
2013-02-22 |
Yeda Res & Dev |
Low frequency glatiramer acetate therapy
|
|
USRE49251E1
(en)
|
2010-01-04 |
2022-10-18 |
Mapi Pharma Ltd. |
Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
|
|
US8759302B2
(en)
|
2010-03-16 |
2014-06-24 |
Teva Pharmaceutical Industries, Ltd. |
Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
|
|
CA2814500A1
(en)
|
2010-10-11 |
2012-04-19 |
Teva Pharmaceutical Industries Ltd |
Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
|
|
HK1200274A1
(en)
|
2011-10-10 |
2015-08-07 |
Teva Pharmaceutical Industries Ltd. |
Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
|
|
HK1213830A1
(zh)
|
2012-10-10 |
2016-07-15 |
Teva Pharmaceutical Industries Ltd. |
用於预测醋酸格拉替雷临床反应的生物标志物
|
|
UY35790A
(es)
|
2013-10-21 |
2015-05-29 |
Teva Pharma |
Marcadores genéticos que predicen la respuesta al acetato de glatiramer
|
|
CN105884866B
(zh)
*
|
2015-01-26 |
2021-04-20 |
漳州未名博欣生物医药有限公司 |
格拉替雷的化学合成方法
|
|
US9155775B1
(en)
|
2015-01-28 |
2015-10-13 |
Teva Pharmaceutical Industries, Ltd. |
Process for manufacturing glatiramer acetate product
|
|
CN112649538B
(zh)
*
|
2015-04-28 |
2024-03-29 |
深圳翰宇药业股份有限公司 |
多肽混合物高效液相色谱分析方法
|
|
US12097292B2
(en)
|
2016-08-28 |
2024-09-24 |
Mapi Pharma Ltd. |
Process for preparing microparticles containing glatiramer acetate
|
|
CN109982712A
(zh)
|
2016-08-31 |
2019-07-05 |
Mapi医药公司 |
包含醋酸格拉替雷的储库系统
|
|
CN110382052A
(zh)
|
2017-03-26 |
2019-10-25 |
Mapi医药公司 |
用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
|
|
WO2019002228A1
(en)
|
2017-06-26 |
2019-01-03 |
Institut Pasteur |
TREATMENTS TO REMOVE HIV RESERVOIRS AND REDUCE VIRAL LOAD
|